Keywords: seattle, antibody, enters, development, genentech, genetics, says

Seattle antibody enters development at Genentech.

Article | 21 January 2002

Seattle Genetics says that its anti-CD40 (PRO64553) monoclonalantibody, used for the treatment of various hematologic malignancies, has entered clinical development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Go to company listing